Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Analyst Ratings

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (?)
Ratings Breakdown: 7 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $74.38 (80.08% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Piper Jaffray Cos.Reiterated RatingOverweight$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016SunTrust Banks Inc.Reiterated RatingTop Pick$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$62.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Royal Bank Of CanadaBoost Price TargetOutperform$62.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Ladenburg ThalmannReiterated RatingBuy$54.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.87)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.66)($0.91)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.49)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.28)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.23)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.23)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.63)($0.69)
Q2 20162($0.79)($0.65)($0.72)
Q3 20163($0.82)($0.66)($0.71)
Q4 20161($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intra-Cellular Therapies (NASDAQ:ITCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
DateHeadline
07/22/16 04:38 PMWere Analysts Bearish Intra-Cellular Therapies Inc (NASDAQ:ITCI) This Week? - Consumer Eagle
07/22/16 04:38 PMIntra-Cellular Therapies Inc (NASDAQ:ITCI) Stock Technicals Hit Strength - CML News
07/20/16 07:43 AMShares Positive Over the Past Month: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - TGP
07/19/16 10:49 AMEquity Roundup: Stock Performance Focus on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Press Telegraph
07/18/16 04:53 PMStock in Positive Territory for the Quarter: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Engelwood Daily
07/17/16 04:15 PMShares Experiencing a Downtrend: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - TGP
07/15/16 08:25 AMCrowd Rating and Earnings Recap for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Telanagana Press
07/15/16 08:25 AMIntra Cellular Therapies Incorporated (NASDAQ:ITCI) Sellers Increased By 1.35% Their Shorts - Consumer Eagle
07/14/16 08:16 AMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 08:16 AMStrong Sell Calls For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0 - Investor Newswire
07/13/16 07:38 AMTrading Performance and Target Watch for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Press Telegraph
07/13/16 07:37 AMHow Analysts Rated Intra-Cellular Therapies Inc (NASDAQ:ITCI) Last Week? - Consumer Eagle
07/11/16 04:47 PMRedmile Group LLC Decreased Stake in Intra Cellular Therapies INC (NASDAQ:ITCI) by $4.53 Million as Shares ... - Engelwood Daily
07/11/16 04:47 PMCompany Stock Focus for Intra-Cellular Therapies Inc. (NASDAQ:ITCI): Which Way Will Shares Head? - Press Telegraph
07/08/16 04:52 PMBullish Two Hundred Day Moving Average Cross - ITCI
07/07/16 03:23 PMINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders -
07/07/16 07:37 AMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/07/16 07:37 AMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Expected to Reach Highs Of $95 - Investor Newswire
07/06/16 09:24 AMStock Rating Watch and Earnings Insight for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Press Telegraph
07/06/16 07:11 AMIntra-Cellular Therapies to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
07/06/16 07:00 AMIntra-Cellular Therapies to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - NEW YORK, July 06, 2016-- Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced that Sharon Mates, ...
07/05/16 04:37 PMCan Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Improve on the Earnings Front? - Engelwood Daily
06/30/16 07:36 AMAre Markets Finally Starting To See Intra-Cellular Therapies, Inc. (ITCI)'s Billion-Dollar Potential? - Insider Monkey (blog)
06/30/16 07:15 AMINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/30/16 06:21 AMIntra-Cellular Therapies Reports Completion of Enrollment of ITI-007-302 Phase 3 Clinical Trial for the Treatment of Schizophrenia - [at noodls] - NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...
06/29/16 04:38 PMStrong Sell Calls Recommendations For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0 - Investor Newswire
06/29/16 12:22 PMAre Markets Finally Starting To See Intra-Cellular Therapies, Inc. (ITCI)’s Billion-Dollar Potential? -
06/29/16 07:31 AMCheck on Share Volatility: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Engelwood Daily
06/28/16 09:35 AMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 09:35 AMIntra-Cellular Therapies (ITCI) Initiated Phase 3 Development of ITI-007 for Dementia - StreetInsider.com
06/28/16 09:35 AMTop Stock Pick for Quarter: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Engelwood Daily
06/27/16 04:41 PMStock Volatility in Review: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Engelwood Daily
06/27/16 03:14 PMIntra-Cellular Therapies, Inc. – Value Analysis (NASDAQ:ITCI) : June 27, 2016 -
06/25/16 04:24 PMIntra-Cellular Therapies Inc. (ITCI) Jumps 5.1% on June 23 - Equities.com
06/24/16 07:37 AMIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bullish Manner : ITCI-US : June 24, 2016 -
06/22/16 04:49 PMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Momentum Hits Weakness - CML News
06/22/16 04:49 PMIntra-Cellular Therapies Inc. (ITCI) Drops 5.33% on June 21 - Equities.com
06/18/16 09:04 AMIntra-Cellular Therapies (ITCI): Today's Weak On High Volume Stock - TheStreet.com
06/15/16 03:17 PMINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 09:20 AMIntra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference - EIN News (press release)
06/15/16 08:09 AMIntra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference - [at noodls] - NEW YORK, June 15, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
06/08/16 05:00 PMINTRA-CELLULAR THERAPIES INC. (NASDAQ:ITCI) Financial Condition Compared to S&P 500 - CML News
06/04/16 07:28 AMPiper Jaffray Indicated Intra-Cellular Therapies (NASDAQ:ITCI) As 'Overweight' - FTSE News
06/04/16 07:28 AMBiotech Movers Update: Intra-Cellular Therapies Inc. (NASDAQ:ITCI) , Accuray Incorporated (NASDAQ:ARAY) - Is stories
06/02/16 04:58 PMIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper Jaffray - Share Trading News - Share Trading NewsIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper JaffrayShare Trading NewsIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper Jaffray. By Brenton Akerman / in US Broker Ratings / on Wednesday, 01 Jun 2016 11:21 PM / 0 Comments. According to a research report issued by Piper Jaffray on Wednesday, ...and more »
06/02/16 06:36 AMCoverage initiated on Intra-Cellular Therapies by Piper Jaffray -
05/31/16 09:02 AMStock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - HNN - Stock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)HNNCovering equity analysts presently have a consensus stock rating of 1 on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...
05/31/16 07:22 AMIntra-Cellular Therapies to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
05/27/16 07:33 PMHold Calls Count For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0 - RealistInvestor.com - Hold Calls Count For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0RealistInvestor.comBuy calls count on Intra-Cellular Therapies Inc. (NASDAQ:ITCI)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has a total of 5 Strong Buy recommendations and 0 Strong Sell ...Earnings Review and Stock Rundown for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and Newsall 540 news articles »
05/26/16 07:27 AMIntra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2016 Annual Meeting - [at noodls] - NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...

Social

About Intra-Cellular Therapies

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ITCI
  • CUSIP:
Key Metrics:
  • Previous Close: $41.30
  • 50 Day Moving Average: $39.14
  • 200 Day Moving Average: $35.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.79B
  • Beta: 0.81
  • Current Year EPS Consensus Estimate: $-3.14 EPS
  • Next Year EPS Consensus Estimate: $-2.94 EPS
Additional Links:
Intra-Cellular Therapies (NASDAQ:ITCI) Chart for Sunday, July, 24, 2016